Tirzepatide vs Retatrutide

Dual versus triple incretin receptor agonists. Here is how the two research peptides compare on class, format and price.

Tirzepatide

Tirzepatide is a synthetic peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It is supplied lyophilised in a 10 mg vial for laboratory and in-vitro research use only.

Tirzepatide is studied in metabolic-signalling research for its combined activity at two incretin receptors, and is frequently compared with single-agonist peptides and with the triple agonist Retatrutide.

Retatrutide

Retatrutide is a synthetic peptide studied as a triple agonist at the GIP, GLP-1 and glucagon receptors. It is supplied lyophilised in a 10 mg vial for laboratory and in-vitro research use only.

As a triple agonist, Retatrutide is studied in metabolic research for activity across three receptor pathways, and is a common comparison point against the dual agonist Tirzepatide.

Which do researchers choose?

Tirzepatide and Retatrutide are dual versus triple incretin receptor agonists. The right choice depends on the research question: they differ in class (GIP / GLP-1 receptor co-agonist vs GGG triple receptor agonist) and strength (10 mg vs 10 mg). Both are supplied lyophilised, third-party HPLC tested, and shipped express post Australia-wide for laboratory and in-vitro research use only.

Frequently asked questions